MedTrace Logo

Blood Biomarkers in Pediatric Kidney Transplant Recipients

NCT05477082 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2025-12-17

No results posted yet for this study

Summary

The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. The study hypothesizes that blood gene expression profile and donor-derived cell-free DNA biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.

Conditions

  • Rejection of Kidney Allograft

Interventions

OTHER

Observational group

Includes blood draws and data collection only

Sponsors & Collaborators

Principal Investigators

  • Sarah Kizilbash, MD · University of Minnesota

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2025-11-16
Completion
2026-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477082 on ClinicalTrials.gov